UroMems Welcomes Rinda Sama to Board as Company Advances Groundbreaking SUI Implant Trials

UroMems Appoints Rinda Sama to Board of Directors

UroMems, a prominent player in the medical technology realm, has made a significant move today by appointing Rinda Sama, a seasoned executive with extensive experience in the medical device industry, to its Board of Directors. This strategic appointment comes as the company gears up for the launch of crucial clinical trials for its innovative UroActive System, which aims to revolutionize the treatment of stress urinary incontinence (SUI).

The Vision for UroActive

UroActive represents a cutting-edge development as the first smart automated implant designed specifically to treat SUI. This condition, affecting approximately 40 million Americans and 90 million Europeans, can severely impair the quality of life, leading to feelings of depression, low self-esteem, and social stigma. UroMems’ mission is to address this urgent need by providing an advanced solution that offers significant improvements over existing treatments.

Rinda Sama, who previously held the position of Chief Operating Officer at Axonics for more than a decade, brings nearly 20 years of experience in the medical device sector. His track record includes successful implementation of operational improvements and rigorous quality systems, which were pivotal for Axonics in securing FDA approval and facilitating their acquisition by Boston Scientific. Prior to Axonics, he played a key role at Vessix Vascular, demonstrating his adeptness in the medical technology field.

“Welcoming Rinda to our board is an incredible opportunity for UroMems,” said Hamid Lamraoui, Co-founder and CEO. “His insightful experience in developing therapies for urinary conditions will be invaluable as we navigate the upcoming pivotal trials for the UroActive System, positioning us well for our forthcoming market launch.”

Rinda Sama’s Insights

Sama expressed his enthusiasm about joining UroMems, highlighting the similarities between UroMems’ current trajectory and Axonics’ past journey. “UroMems is positioned much like Axonics was years ago, at the forefront of bringing a groundbreaking treatment to patients after a prolonged period of limited innovation in the field,” he stated. “I anticipate the UroActive System has the potential to transform how SUI is treated, and I am eager to leverage my operational expertise to drive the project through regulatory approval and into the marketplace.”

Achievements and Next Steps

UroMems has recently accomplished crucial milestones in its development process, particularly with strong results from a multicenter clinical study that indicate the efficacy of its technology. Having secured $47 million in funding, the company is now poised for extensive U.S. and European trials of the UroActive System, with aims to commence these operations imminently.

The UroActive implant, leveraging a unique mechatronic platform, operates using advanced digital and robotic systems that tailor treatment algorithms specific to individual patient needs. This approach is backed by an impressive portfolio of over 150 patents, reflecting UroMems’ commitment to enhancing safety, performance, and patient experience.

SUI can have a profound impact on individuals, often leading to significant lifestyle limitations. UroMems is dedicated to advancing this technology, which aims not just to provide a solution but to redefine patient expectations and outcomes. As the company prepares for the critical phase of clinical trials, the appointment of Rinda Sama is expected to further solidify its pathway towards successful market introduction.

For those interested in the advancements in medical technology and innovative treatments for conditions like SUI, UroMems is a name to watch in the near future.